Details of Disease

General Information of Disease (ID: DISDXEHY)

• Disease Name: Chikungunya virus infection
• Synonyms: CK; arbovirus A Chikungunya type; CHIK; CHIKV infection; Chikungunya virus infection; Chikungunya fever; Chikungunya virus infectious disease; Chikungunya virus disease or disorder; Chikungunya virus caused disease or disorder
• Disease Class: 1D40: Chikungunya virus disease
• Definition: An infection that is caused by the Chikungunya virus, which is transmitted by mosquitoes; it is characterized by fever and severe arthralgia.
• Disease Hierarchy:
  DISGFCIX: Vector-borne disease
  DISZGSCJ: Alphavirus infectious disease
  DIS7HTZ7: Arbovirus fever
  DISEM33Q: Infectious disease
  DISDXEHY: Chikungunya virus infection
• ICD Code:
  ICD-11: ICD-11: 1D40
  ICD-9: ICD-9: 001-139, 042-075
  Expand ICD-9: 001,002,003,004,005,006,007,008,009,010,011,012,013,014,015,016,017,018,019,020,021,022,023,024,025,026,027,028,029,030,031,032,033,034,035,036,037,038,039,040,041,042,043,044,045,046,047,048,049,050,051,052,053,054,055,056,057,058,059,060,061,062,063,064,065,066,067,068,069,070,071,072,073,074,075,076,077,078,079,080,081,082,083,084,085,086,087,088,089,090,091,092,093,094,095,096,097,098,099,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139
• Disease Identifiers:
  MONDO ID: MONDO_0017941
  MESH ID: D065632
  UMLS CUI: C0008055
  MedGen ID: 3362
  Orphanet ID: 324625
  SNOMED CT ID: 111864006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VLA1553	DMIY48N	Phase 3	Vaccine	[1]
Chikungunya vaccine	DMF6ABT	Phase 2	NA	[2]
Chikungunya virus vaccine	DMM51YM	Phase 2	NA	[3]
CHIKV VLP	DM8U055	Phase 2	Vaccine	[4]
Live attenuated recombinant vaccine	DMUQYDT	Phase 2	NA	[5]
MV-CHIK	DM6CUJT	Phase 2	Vaccine	[6]
V184	DMIDJBY	Phase 2	Vaccine	[7]
mRNA-1388	DMRW1QL	Phase 1	NA	[2]
mRNA-1944	DM8Z9MN	Phase 1	mRNA therapy	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
G3BP1	TTG0R8Z	Limited	Biomarker	[9]
CD209	TTBXIM9	Strong	Genetic Variation	[10]
CPE	TTXPWO6	Strong	Biomarker	[11]
HLA-DQB2	TTL7VOU	Strong	Genetic Variation	[12]
IFNAR2	TTMQB37	Strong	Biomarker	[13]
IFNL1	TTM624L	Strong	Biomarker	[14]
IRF3	TTYR7OH	Strong	Biomarker	[15]
KIR2DL1	TT4UXPE	Strong	Biomarker	[16]
LILRB2	TTHC6XU	Strong	Altered Expression	[17]
SLAMF6	TTSIYJ6	Strong	Altered Expression	[18]
SLC15A3	TTAYPWS	Strong	Biomarker	[19]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C4	DEAJN47	Strong	Biomarker	[20]

This Disease Is Related to 36 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LAMP3	OTN0XL3W	Limited	Biomarker	[21]
LSAMP	OTYXVQX2	Limited	Biomarker	[21]
SH2D3A	OTVJBSRC	Limited	Altered Expression	[22]
SH2D3C	OTAGXO0N	moderate	Biomarker	[23]
ATP2C1	OTQN51T3	Strong	Biomarker	[24]
CTRL	OTB6NA5O	Strong	Biomarker	[25]
DHX40	OTOL02QN	Strong	Biomarker	[26]
EEF2	OTZ7SZ39	Strong	Biomarker	[27]
EIF4A1	OTMTBX6N	Strong	Biomarker	[28]
EIF4A2	OT08H03R	Strong	Biomarker	[28]
ENOPH1	OTKXMWNN	Strong	Biomarker	[29]
EPRS1	OTXK0FLB	Strong	Biomarker	[30]
G3BP2	OTAWW3KI	Strong	Biomarker	[31]
GOLPH3	OTDLGYM3	Strong	Biomarker	[32]
GZMA	OT43R33L	Strong	Biomarker	[33]
IFI16	OT4SPU0U	Strong	Altered Expression	[34]
KLRD1	OTMYLOV4	Strong	Altered Expression	[18]
MAVS	OTTQ0J64	Strong	Biomarker	[20]
MPG	OTAHW80B	Strong	Biomarker	[35]
MXRA8	OT43JEP1	Strong	Biomarker	[36]
NDST1	OT9E10W2	Strong	Biomarker	[37]
NUTF2	OT8VA2ZF	Strong	Biomarker	[9]
OAS1	OT8ZLOCY	Strong	Genetic Variation	[10]
OAS2	OT64CCTM	Strong	Genetic Variation	[10]
OAS3	OT6E5FYS	Strong	Genetic Variation	[10]
PARS2	OTMBBH7K	Strong	Biomarker	[30]
POLR3K	OTZCSF6A	Strong	Biomarker	[20]
PRSS57	OTR6GDQM	Strong	Biomarker	[38]
PTOV1	OT94WT5X	Strong	Biomarker	[39]
RSAD2	OTCA9WCM	Strong	Biomarker	[40]
SAMHD1	OTBCIBC7	Strong	Biomarker	[41]
SARS1	OTFKXQ1O	Strong	Biomarker	[42]
SARS2	OTU4T99W	Strong	Biomarker	[42]
SIGLEC9	OTZC7SIM	Strong	Altered Expression	[43]
SNX5	OT6ZOWMU	Strong	Biomarker	[44]
TM9SF2	OTA0C202	Strong	Biomarker	[37]

References

• [1] ClinicalTrials.gov (NCT04838444) Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Takeda.
• [4] ClinicalTrials.gov (NCT03483961) Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01511250) Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT02861586) Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202). U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03807843) Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults. U.S.National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03829384) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults. U.S. National Institutes of Health.
• [9] Separate domains of G3BP promote efficient clustering of alphavirus replication complexes and recruitment of the translation initiation machinery.PLoS Pathog. 2019 Jun 14;15(6):e1007842. doi: 10.1371/journal.ppat.1007842. eCollection 2019 Jun.
• [10] Association of Oligoadenylate Synthetase Gene Cluster and DC-SIGN (CD209) Gene Polymorphisms with Clinical Symptoms in Chikungunya Virus Infection.DNA Cell Biol. 2016 Jan;35(1):44-50. doi: 10.1089/dna.2015.2819. Epub 2015 Sep 23.
• [11] Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.Bioorg Med Chem. 2017 Jan 1;25(1):327-337. doi: 10.1016/j.bmc.2016.10.037. Epub 2016 Oct 31.
• [12] Association of human leukocyte antigen class II allele and haplotypes in chikungunya viral infection in a western Indian population.Trans R Soc Trop Med Hyg. 2014 May;108(5):277-82. doi: 10.1093/trstmh/tru030. Epub 2014 Apr 2.
• [13] Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.J Virol. 2017 Feb 28;91(6):e02154-16. doi: 10.1128/JVI.02154-16. Print 2017 Mar 15.
• [14] IL-27 in patients with Chikungunya fever: A possible chronicity biomarker?.Acta Trop. 2019 Aug;196:48-51. doi: 10.1016/j.actatropica.2019.05.005. Epub 2019 May 7.
• [15] Infectious Chikungunya Virus in the Saliva of Mice, Monkeys and Humans.PLoS One. 2015 Oct 8;10(10):e0139481. doi: 10.1371/journal.pone.0139481. eCollection 2015.
• [16] Association of HLA class-I and inhibitory KIR genotypes in Gabonese patients infected by Chikungunya or Dengue type-2 viruses.PLoS One. 2014 Sep 29;9(9):e108798. doi: 10.1371/journal.pone.0108798. eCollection 2014.
• [17] Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs.Cell Mol Life Sci. 2018 May;75(10):1871-1887. doi: 10.1007/s00018-017-2712-9. Epub 2017 Nov 13.
• [18] Differential inhibitory and activating NK cell receptor levels and NK/NKT-like cell functionality in chronic and recovered stages of chikungunya.PLoS One. 2017 Nov 28;12(11):e0188342. doi: 10.1371/journal.pone.0188342. eCollection 2017.
• [19] The Solute Carrier Transporter SLC15A3 Participates in Antiviral Innate Immune Responses against Herpes Simplex Virus-1.J Immunol Res. 2018 Jul 5;2018:5214187. doi: 10.1155/2018/5214187. eCollection 2018.
• [20] Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway.J Virol. 2018 Feb 26;92(6):e01913-17. doi: 10.1128/JVI.01913-17. Print 2018 Mar 15.
• [21] Development of a single-tube one-step RT-LAMP assay to detect the Chikungunya virus genome.PLoS Negl Trop Dis. 2018 May 29;12(5):e0006448. doi: 10.1371/journal.pntd.0006448. eCollection 2018 May.
• [22] Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase.FEBS Lett. 2020 Feb;594(4):678-694. doi: 10.1002/1873-3468.13642. Epub 2019 Nov 2.
• [23] The Host DHX9 DExH-Box Helicase Is Recruited to Chikungunya Virus Replication Complexes for Optimal Genomic RNA Translation.J Virol. 2019 Feb 5;93(4):e01764-18. doi: 10.1128/JVI.01764-18. Print 2019 Feb 15.
• [24] Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread.Cell Host Microbe. 2017 Oct 11;22(4):460-470.e5. doi: 10.1016/j.chom.2017.09.002.
• [25] Structure-function insights into chikungunya virus capsid protein: Small molecules targeting capsid hydrophobic pocket.Virology. 2018 Feb;515:223-234. doi: 10.1016/j.virol.2017.12.020. Epub 2018 Jan 5.
• [26] Detection of chikungunya virus-specific IgM on laser-cut paper-based device using pseudo-particles as capture antigen.J Med Virol. 2019 Jun;91(6):899-910. doi: 10.1002/jmv.25420. Epub 2019 Feb 8.
• [27] Global protein profiling studies of chikungunya virus infection identify different proteins but common biological processes.Rev Med Virol. 2015 Jan;25(1):3-18. doi: 10.1002/rmv.1802. Epub 2014 Jul 27.
• [28] Silvestrol Inhibits Chikungunya Virus Replication.Viruses. 2018 Oct 30;10(11):592. doi: 10.3390/v10110592.
• [29] Proteomics profiling of chikungunya-infected Aedes albopictus C6/36 cells reveal important mosquito cell factors in virus replication.PLoS Negl Trop Dis. 2015 Mar 4;9(3):e0003544. doi: 10.1371/journal.pntd.0003544. eCollection 2015 Mar.
• [30] A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses.Antiviral Res. 2019 Jan;161:163-168. doi: 10.1016/j.antiviral.2018.11.017. Epub 2018 Dec 3.
• [31] Stress granule components G3BP1 and G3BP2 play a proviral role early in Chikungunya virus replication.J Virol. 2015 Apr;89(8):4457-69. doi: 10.1128/JVI.03612-14. Epub 2015 Feb 4.
• [32] Assembly of tomato blistering mosaic virus-like particles using a baculovirus expression vector system.Arch Virol. 2019 Jul;164(7):1753-1760. doi: 10.1007/s00705-019-04262-5. Epub 2019 Apr 25.
• [33] RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.PLoS Pathog. 2017 Feb 16;13(2):e1006155. doi: 10.1371/journal.ppat.1006155. eCollection 2017 Feb.
• [34] Interferon-inducible protein (IFI) 16 regulates Chikungunya and Zika virus infection in human skin fibroblasts.EXCLI J. 2019 Jun 27;18:467-476. doi: 10.17179/excli2019-1271. eCollection 2019.
• [35] Regulation of Viral Replication, Apoptosis and Pro-Inflammatory Responses by 17-AAG during Chikungunya Virus Infection in Macrophages.Viruses. 2017 Jan 6;9(1):3. doi: 10.3390/v9010003.
• [36] Structures Unveil the Invasion Mechanism of Chikungunya Virus.Trends Microbiol. 2019 Aug;27(8):656-658. doi: 10.1016/j.tim.2019.05.011. Epub 2019 Jun 17.
• [37] Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection.J Virol. 2017 Jun 9;91(13):e00432-17. doi: 10.1128/JVI.00432-17. Print 2017 Jul 1.
• [38] An amino acid change in nsP4 of chikungunya virus confers fitness advantage in human cell lines rather than in Aedes albopictus.J Gen Virol. 2019 Nov;100(11):1541-1553. doi: 10.1099/jgv.0.001338.
• [39] Spectral characterisation, antiviral activities, in silico ADMET and molecular docking of the compounds isolated from Tectona grandis to chikungunya virus.Biomed Pharmacother. 2017 Mar;87:302-310. doi: 10.1016/j.biopha.2016.12.069. Epub 2017 Jan 4.
• [40] Viperin restricts chikungunya virus replication and pathology.J Clin Invest. 2012 Dec;122(12):4447-60. doi: 10.1172/JCI63120. Epub 2012 Nov 19.
• [41] SAMHD1 Enhances Chikungunya and Zika Virus Replication in Human Skin Fibroblasts.Int J Mol Sci. 2019 Apr 5;20(7):1695. doi: 10.3390/ijms20071695.
• [42] Identification of 6'--fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication.Eur J Med Chem. 2020 Feb 1;187:111956. doi: 10.1016/j.ejmech.2019.111956. Epub 2019 Dec 9.
• [43] Oxidative damage markers and inflammatory cytokines are altered in patients suffering with post-chikungunya persisting polyarthralgia.Free Radic Res. 2018 Aug;52(8):887-895. doi: 10.1080/10715762.2018.1489131. Epub 2018 Jul 23.
• [44] Comparative Characterization of the Sindbis Virus Proteome from Mammalian and Invertebrate Hosts Identifies nsP2 as a Component of the Virion and Sorting Nexin 5 as a Significant Host Factor for Alphavirus Replication.J Virol. 2018 Jun 29;92(14):e00694-18. doi: 10.1128/JVI.00694-18. Print 2018 Jul 15.